Loading stock data…
Nautilus Biotechnology, Inc. (NAUT)
$0.93+0.02 (+2.54%)
Market ClosedLast close Sep 8
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nautilus Biotechnology, Inc. in the Healthcare sector is trading at $0.93 with a market capitalization of $118M. Wall Street consensus targets $4.00 (1 analysts), implying a +331.1% move over the next 12 months. The stock is currently near its 52-week low of $0.68, remaining 57.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +331.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10,000 | $0 | $0 | $0 | $0 |
| Gross Profit | -$5,000 | — | — | — | $0 |
| Operating Income | -$15.76M↑ | -$16.12M↓ | -$15.42M↑ | -$15.47M↑ | -$17.10M |
| Net Income | -$14.47M↑ | -$14.70M↓ | -$13.78M↓ | -$13.57M↑ | -$15.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$118.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.11%
Volume
Today's trading volume
1.07M
Recent News
Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...
Nautilus Biotechnology Inc (NAUT) leverages proteoform advancements and strategic collaborations to drive future growth amid financial challenges.
Nautilus Biotechnology Q2 Earnings Call Highlights
Nautilus Biotechnology (NASDAQ:NAUT) said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program. Chief Executive Officer Sujal Patel said the company’s platform has d
3 Penny Stocks With Market Caps Over $100M To Watch
The market is up 1.2% over the last week, and in the past year, it has climbed an impressive 27%, with earnings expected to grow by 17% per annum. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when built on solid financials. We've identified three penny stocks that demonstrate financial strength and potential for growth, offering investors a chance to uncover hidden value in quality...
3 Promising Penny Stocks With Market Caps Up To $900M
The market remained flat over the last week, yet it is up 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In this context, identifying stocks that combine solid financials with growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks, often associated with smaller or newer companies, continue to be relevant as they can offer significant returns when backed by strong fundamentals.
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...